The myogenic program is controlled by different groups of transcription factors acting during muscle development, including bHLH muscle regulatory factors (MRFs), the paired factors Pax3 and Pax7 and the homeobox factors Six1 and Six4. This program is critically dependent on MRFs that target downstream muscle-specific genes. We now report the expression of Pitx2 and Pitx3 transcription factors throughout muscle development. Pitx2 is first expressed in muscle progenitor cells of the dermomyotome and myotome. The onset of myoblast differentiation is concomitant with expression of Pitx3; its expression is maintained in all skeletal muscles while Pitx2 expression decreases thereafter. We have generated Pitx3 mutant mice and this deficiency does not significantly perturb muscle development but it is completely compensated by the maintenance of Pitx2 expression in all skeletal muscles. These experiments suggest that Pitx genes are important for myogenesis and that Pitx2 and Pitx3 may have partly redundant roles.
Introduction
The skeletal muscles of the body and limbs are derived from somites that segment the elongating embryo along the anteriorposterior axis. The somites rapidly separate into a ventral mesenchymal compartment, the sclerotome, and a dorso-lateral epithelial compartment, the dermomyotome. Cells delaminate at the dorsal and ventral lips of the dermomyotome to form the myotome along its medial surface (Christ and Ordahl, 1995; Tajbakhsh and Buckingham, 2000) . Multipotent muscle progenitor cells arising in the dermomyotome acquire definitive identity through the action of the myogenic regulatory factors (MRFs) Myf5, Mrf4 and MyoD (Rudnicki, 2003; Tajbakhsh et al., 1996; Kassar-Duchossoy et al., 2004) . These progenitors give rise to muscle precursors, the myoblasts present in the myotome (Smith et al., 1994; Tajbakhsh, 2003) under the influence of myogenin, MyoD and Mrf4 . The myotome is a transient structure and its role appears to be the establishment of the original muscle masses that form through elongation. Myoblasts from the medial/dorsal myotome will develop into epaxial muscles and intrinsic back muscles whereas cells of lateral/ventral portion of the dermomyotome and of the lateral myotome will develop into hypaxial muscles which include intercostal, abdominal and limb muscles as well as the diaphragm and tongue muscles (Buckingham et al., 2003) . At the level of developing limbs, cells that delaminate from the ventral hypaxial lip of the dermomyotome migrate towards the developing limb buds and establish themselves in the early muscle territories of the limbs (Scaal et al., 1999; Dietrich, 1999; Christ and Brand-Saberi, 2002) ; these territories appear to be defined independently of muscle progenitor cells (Kardon et al., 2003) . These migratory cells require Pax3 for proper migration and establishment of limb muscle masses (Bober et al., 1994; Daston et al., 1996; Tremblay et al., 1998b) . Indeed, a migration defect was ascribed to the failure to express the receptor tyrosine kinase c-met in the absence of Pax3 (Bladt et al., 1995; Epstein et al., 1996; Birchmeier and Brohmann, 2000) . Migrating progenitor cells also express Mox2 and Lbx-1 which are required for migration and under the control of Pax3 (Mankoo et al., 1999; Mennerich et al., 1998; Schafer and Braun, 1999; Gross et al., 2000) .
Pax7, a Pax3 paralogue, has also been implicated in the specification of cells that enter the myogenic program. In the absence of both Pax3 and Pax7, there is a major deficit in skeletal muscle development with the arrest of the myogenic program occurring during late embryonic and fetal development (Relaix et al., 2005) . Indeed in this mutant, cells which should have expressed these two genes die or change cell fate. Interestingly, Pax7 is not expressed in early embryonic muscle progenitors present at the edges of the dermomyotome. Rather, Pax3/Pax7-positive cells are derived from the central part of the dermomyotome (Ben Yair and Kalcheim, 2005; Gros et al., 2005) . These cells can either activate the myogenic program through the action of Myf5 and MyoD or remain as a proliferating progenitor population that reside within the muscle mass (Gros et al., 2005; KassarDuchossoy et al., 2005; Relaix et al., 2005) . In late-stage fetal muscle, these cells adopt a satellite cell position, suggesting that they can become the pool of adult satellite cells responsible for postnatal skeletal muscle growth and integrity (Gros et al., 2005; Kassar-Duchossoy et al., 2005; Relaix et al., 2005) .
Two homeobox genes related to drosophila sine oculis (Six1 and Six4) are also expressed in muscle cells starting in dermomyotome and myotome (Ozaki et al., 2001; Laclef et al., 2003; Grifone et al., 2005) . Inactivation of both genes appears to prevent myogenic precursor delamination and migration, in part through deficient Pax3 expression and in part through deficient MRF expression (Grifone et al., 2005) . These different studies clearly illustrate that the pathway for control of myogenesis is not linear and includes many inputs whose interrelations are not well defined.
Prior work has shown expression of the homeobox transcription factor Pitx2 in what appeared to be myotomes and putative migrating myoblasts (Logan et al., 1998; Kioussi et al., 2002) . The related Pitx3 is also expressed in somites (Zhao et al., 2004) and we have recently identified a muscle-specific promoter responsible for its expression in myotome and muscles (Coulon et al., submitted for publication) . Otherwise, Pitx2 has been implicated in left-right asymmetry (Yoshioka et al., 1998; Logan et al., 1998; Piedra et al., 1998; Ryan et al., 1998) , in cranio-facial development and in pituitary function as indicated by the name of these factors (Lin et al., 1999; Lu et al., 1999; Gage et al., 1999) . Pitx3 is required for ocular development (Semina et al., 1997; Semina et al., 1998) and for the development (Smidt et al., 2004 ) and maintenance of a subset of midbrain dopaminergic neurons (Smidt et al., 1997; van den Munckhof et al., 2003 van den Munckhof et al., , 2006 .
We now report the detailed investigation on the expression of Pitx2 and Pitx3 during myogenesis. Pitx2 is expressed the earliest in muscle progenitor cells. This expression is followed and partly overlapping with the appearance of Pitx3 in differentiated muscle cells. Pitx3 then appears to be widely expressed in all skeletal muscles of the body and limbs. The investigation of Pitx3 −/− mice indicates that Pitx3 on its own is not required for myogenesis. However, Pitx2 is strongly upregulated in the absence of Pitx3 and appears to fully compensate during muscle formation. Taken collectively, these data suggest that Pitx genes are important for myogenesis and that their activities may be partly redundant.
Materials and methods

Construction of Pitx3 gene targeting vector
Pitx3 genomic DNA was cloned from a 129sv genomic library. Genomic fragments corresponding to the Pitx3 locus were cloned into pBluescript KS+ (for construction of a targeting vector, Fig. 5 ). Homologous recombination with this vector will lead to insertion of a fragment containing the neomycin resistance gene flanked by FRT sites and to insertion of LoxP sites upstream of the neo cassette and downstream of exon 3. Expression of Cre recombinase should lead to excision of this whole fragment, including Pitx3 exon 3 that codes for the homeodomain responsible for the DNA binding activity of Pitx3.
ES cell screening and chimeric mouse production
Linearized targeting DNA was electroporated (250 V, 500 μF) into embryonic stem (ES) cells. ES cells were selected with 250 μg/ml of G418 48 h after electroporation. The DNA of ≈600 resistant clones was analyzed by Southern blot after digestion. A 3′ genomic fragment was used as external probe. Three independent homologous recombinant clones were identified and microinjected into C57BL6 blastocysts for implantation into pseudopregnant mice. Chimeric males were obtained for the 3 clones and tested for germline transmission. Two chimeric males were chosen and heterozygous progenies were generated by backcrosses to C57BL6 and 129/SvJ females. Pitx2 −/− and CMV-Cre transgenic mice were described previously (Gage et al., 1999) .
Mouse genotyping
Genotyping was carried out by PCR using DNA isolated from the umbilical cord/amniotic membrane of the embryos or adult tail sections. Separate reactions were carried out for Pitx3 and Cre genotyping. Three specific primers were used for Pitx3 alleles: one forward primer in intron 2: 5′-GGGAGCGAGAGTGATAACCT-3′, and two reverse primers located in intron 3: 5′-GGAACAGCTCGGGATCAAAG-3′ and in the neomycin gene 5′-TAC-CGGTGGATGTGGAATGT-3′. Two primers were used for Cre detection: forward primer 5′-ATCCGAAAAGAAAACGTTGA-3′ and reverse primer 5′-ATCCAGGTTACGGATATAGT-3′. For embryo studies, noon of the day on which a vaginal plug was detected was considered as e0.5. Embryos were staged more precisely by counting the number of somites posterior to the forelimb bud and scoring the first one counted as somite 13 (Lewandoski et al., 2000) .
Preparation and characterization of affinity-purified anti-Pitx2 and anti-Pitx3 antibodies Antibodies were raised in rabbits using 100 μg MBP-Pitx2 or MBP-Pitx3 for the primary injection and three subsequent boosts. Affinity purification was performed as previously described (Lanctôt et al., 1999b) except that a GSTPitx2 or Pitx3 column was used. Two different antisera were produced against MBP fusion antigens containing amino acids 1-38 of mouse Pitx2 protein and amino acids 121-180 of mouse Pitx3.
Histology, immunohistochemistry and immunofluorescence
Histology and section immunohistochemistry was performed as described (Lanctôt et al., 1999a ) using rabbit anti-Pitx2 (1/250), rabbit anti-Pitx3 (1/ 250) and a previously described rabbit Pitx1 antibody (Tremblay et al., 1998a) . Other primary antibodies were purchased from Pharmingen (antimouse MyoD 1/100 and myogenin 1/100) or from the Developmental Studies Hybridoma Bank developed under the auspices of the NICHD and maintained by the University of Iowa, Department of Biological Sciences, Iowa City, IA 52242 (anti-mouse α-actin, MF20 1/20, Pax3 1/100 and Pax7 1/10). Biotinylated anti-mouse and anti-rabbit (Vector Labs, 1/150) were used as secondary antibodies and revealed using streptavidin-HRP (NEL 750, NEN, 1/1000) and DAB for immunohistochemistry. Slides were then counterstained with Methyl Green. For immunofluorescence, biotinylated anti-rabbit, anti-mouse-Alexa 488 or 546, and streptavidin-Alexa 488 or 546 (Vector Labs, 1/150) were used as secondary or tertiary antibodies. Slides were mounted using Vecta-Shield (Vector Labs). For Pitx3 and Pax7 co-staining, rabbit anti-Pitx3 (1/250) and anti-rabbit alkaline phosphatase (Vector Labs, 1/ 300) were used together with mouse anti-Pax7 (1/10), biotinylated anti-mouse (Vector Labs, 1/150) and streptavidin-HRP (NEL 750, NEN, 1/1000). The reactions were revealed using NBT/BCIP (Roche Diagnostics) and NovaRED (Vector Labs) substrates. No counter-staining was performed and slides were mounted using aqueous medium (9:1 glycerol/PBS).
Whole-mount in situ hybridization
Sections and whole-mount in situ hybridization was performed as described in the protocols from Dr. Janet Rossant's laboratory using Pitx2 and Pitx3 probes. These two protocols used can be found at http://www.sickkids.ca/ rossant/custom/protocols.asp.
Results
Expression of Pitx2 and Pitx3 in muscle cells
The embryonic pattern of Pitx gene expression was revealed by whole-mount in situ hybridization. For both Pitx2 and Pitx3, expression was detected in myotome and in forming muscles masses of limb buds . This expression appears later than the Pitx2 expression in oral ectoderm and lateral plate mesoderm that are already evident at e9.5 (Fig. 1A) . Examination of multiple embryos suggested that myotome expression of Pitx2 and Pitx3 starts around e10.5 and that both are well established by e11, with Pitx2 signal appearing stronger than that of Pitx3 ( and this is illustrated for hindlimb (HL) muscles at e12.5 (Figs. 1D and H) .
In order to correlate the expression of Pitx2 and Pitx3 with myotome and/or dermomyotome development, sequential transverse sections from e10.5 embryos taken at the level of forelimb (FL) and HL buds were analyzed by immunohistochemistry for Pitx factors and for markers of myogenesis (Figs. 1I-R). At the FL level, expression of Pitx2 is first detected in the hypaxial part of the myotome (Fig. 1L) , defined by myogenin (Fig. 1I ) and MF20 staining (Fig. 1J) . It is also expressed in the ventro-lateral lip (vll) of the dermomyotome (Fig. 1L) , delineated by Pax3 staining (Fig. 1K) . No expression is detected at this stage at the HL level (Fig. 1Q) . Serial sections stained for Pitx3 reveal expression in the hypaxial part of rostral myotomes but not in dermomyotome (Fig. 1M) , in contrast to Pitx2. Interestingly, neither Pitx gene is expressed in less developed myotomes at HL level (Figs. 1Q, R), whereas Pax3 and myogenin are already detected (Figs. 1N, P), suggesting that Pitx2 and Pitx3 switch on after myogenic commitment in myotome. In addition, migratory cells (arrowhead) and HL precursors expressing Pax3 do not express Pitx genes (Fig. 1P) . At later developmental stages (data not shown), caudal myotomes exhibit Pitx expression patterns similar to those of e10.5 rostral myotomes.
Sequential expression of Pitx2 and Pitx3
In order to better define expression of Pitx2 and Pitx3 genes during myotome development, we investigated their expression by co-localization with various markers in e11.5 myotomes that are progressively more advanced in development along the anterior to posterior axis (Fig. 2) . In these embryos, the least developed myotomes at the caudal end show a significant number of nuclei positive for Pitx2 (Figs. 2D and J), but very few positive for Pitx3 (Figs. 2P and V) . Co-labeling with myogenin and MF20 indicates that many cells co-express these differentiation markers with Pitx2 (Figs. 2F, L1 and 3Y). It is interesting to note that Pitx2-positive and MF20-negative cells are present at the ventral lip of the dermomyotome (Fig. 2L2) . Taken together, these data suggest that Pitx2 is expressed before Pitx3 in myotome; in agreement with its expression in vll (Figs. 1L and 2L2), Pitx2 may be associated with cell progression from dermomyotome to myotome.
The same co-labeling experiments were performed in more advanced rostral somites and showed a majority of Pitx3-positive cells co-expressing myogenin (Figs. 2M-O, 3Z) and MF20 (Figs. 2S-U). In contrast, only a fraction of Pitx2-positive cells express these markers ( Figs. 2A-C, G-I, 3Y ). These results suggest that Pitx3 is expressed in differentiated myotome cells, and that Pitx2 may be expressed earlier in muscle progenitors and precursors.
Pitx2 is expressed in muscle precursors while Pitx3 appears at differentiation
In order to determine if the Pitx2-positive MF20-negative cells of the myotome and vll are muscle progenitor cells, we performed co-staining of Pitx2 with Pax3 (Figs. 3A-C) : indeed, many of these vll cells co-express Pitx2 and Pax3 (Fig. 3C2) . In the central myotome, most Pitx2-positive cells are also Pax3-positive (Fig. 3C1) . We then checked Pitx2 and Pitx3 expression at limb level in migrating myoblast precursors by co-labeling with Pax3; we did not find any co-labeling in migrating cells in agreement with Figs. 1K, L and P, Q. Interestingly, all Pax3-positive cells that have completed migration at the proximal limb bud also express Pitx2 (Figs. 3D-I) . However, all Pitx2-positive cells are not positive for Pax3: these may represent myoblast cells that have entered differentiation. In parallel co-labeling experiments, Pitx3 was never co-expressed with Pax3 (data not shown).
Pax7 is expressed with Pax3 in a large subset of muscle progenitors (Relaix et al., 2005) . In agreement with the interpretation that muscle progenitors express Pitx2, we found extensive co-labeling of myotome cells with Pitx2 and Pax 3 (Fig. 3C1) , and with Pax7 (Figs. 3J-L) . In order to assess whether Pitx2-positive cells are indeed proliferating progenitors, we performed BrdU incorporation in e11.5 embryos (Figs. 3M-O, Y) . Analysis of developing FL muscle masses indicated that a large number of Pitx2-positive cells incorporated BrdU (Figs. 3O, Y) . In contrast, co-staining for Pitx3 revealed fewer double-positive cells with BrdU (Figs. 3V-X, Z) . Phospho-histone H3 is a marker of early mitosis and in agreement with the idea that Pitx2-positive progenitors are in proliferation, we detected cells positive for both Pitx2 and phospho-H3 in interlimb myotomes of e11.5 embryos (Figs. 3P-R, Y) . In contrast, double-positive cells for phospho-H3 and Pitx3 could only rarely (about 1.5%) be observed (Fig. 3Z) , suggesting that the few Pitx3-and BrdUpositive cells (Figs. 3X, Z) correspond to cells that recently exited the cell cycle. In order to test the idea that Pitx3 switches on at the onset of muscle differentiation, we did colabeling of myotomal and limb muscle masses with Pitx3 and the MRFs MyoD and myogenin (Fig. 3Z) . Whereas in myotome, about 80% of Pitx3-positive cells are also myogenin-positive, we observed fewer double-positive cells in limb muscles (about 40%); it is however noteworthy that all limb bud myogenin-positive cells are also Pitx3-positive (Figs. 3S-U) . It is also interesting to note different proportions of double MRF-and Pitx2-positive cells in myotome compared to limb muscle masses (Fig. 3Y) . These data may suggest that Pitx3 expression precedes MRFs in limb bud muscles, in contrast to myotomes.
Maintenance of Pitx3 and decreasing Pitx2 expression
Whole-mount in situ hybridization revealed that both Pitx2 and Pitx3 genes have similar patterns of expression in embryonic developing muscles (Fig. 1) . Since Pitx3 early expression suggests widespread presence in all skeletal muscles, we verified its expression in muscles of e15.5 embryos by in situ hybridization. This analysis (Figs. 4A-C) confirmed Pitx3 mRNA in HL muscles as well as in abdominal and back muscles that derive from hypaxial and epaxial myotome, respectively.
In order to assess the relative expression of Pitx2 and Pitx3 in developing muscles, we followed their expression during fetal development in a variety of muscles. While Pitx2 expression is already well established at e11.5 in shoulder girdle muscle (Fig. 4D) together with MyoD and myogenin (Figs. 4F, G) , fewer Pitx3-positive cells are detected in these muscles (Fig. 4E) . In contrast, by e13.5 the same muscles exhibit a strong Pitx3 signal (Fig. 4I ), but greatly decreased Pitx2 (Fig. 4H ). This switch in relative expression of Pitx2 and Pitx3 is also evident for many muscles on a low magnification view of e13.5 FL (Figs. 4L, M) . It is interesting to note that staining of serial limb sections for Pitx2, Pitx3 and α-actin showed a close correlation between Pitx3, but less so for Pitx2, and α-actin expression (data not shown), in agreement with the conclusion that Pitx3 is expressed in differentiated muscle cells. This is further supported in e17.5 muscles that all show strong Pitx3 expression (Fig. 4Q ) but very weak Pitx2 (Fig. 4P) . In order to directly assess Pitx3 expression in satellite cells, we did co-labeling of e18.5 hindlimb muscles with Pitx3 and Pax7 (Fig. 4R ). This analysis revealed that most Pax7-positive nuclei are also Pitx3-positive, in addition to a population of Pitx3 singlepositive nuclei. These data indicate expression of Pitx3 in both muscle fiber and satellite cells. 
embryos at rostral (A-C, G-I), thoracic (M-O, S-U) and caudal (D-F, J-L, P-R, V-X) levels.
Pitx3 expression in caudal myotome is restricted to a few cells (P-R, V-X), whereas a significant number of cells are positive for Pitx2 (D-F, J-L). A majority of these cells co-express both myogenin (D-F) and MF20 (J-L, L1), but interestingly, a population of Pitx2-positive cells located in the ventro-lateral part of dermomyotome (L2) do not express MF20. The same co-staining performed at thoracic and rostral levels show a large number of Pitx3-positive cells that mostly co-express myogenin (M-O) and MF20 (S-U), whereas only a fraction of Pitx2-expressing cells are positive for these markers (A-C, G-I). 
Normal myogenesis in Pitx3 mutant embryos
Since Pitx3 is the most widely expressed Pitx factor in fetal muscles (Fig. 4) , we undertook to knockout this gene. For this purpose, the naturally occurring Pitx3 mutant, the aphakia mouse, is not useful since this mouse retains muscle expression of Pitx3 (Coulon et al., submitted for publication). For Pitx3 gene inactivation, we targeted the third exon of the gene that encodes the homeodomain (Fig.  5A) . LoxP sites were introduced upstream and downstream of exon 3 in a vector that also contains a PGKneo cassette flanked by FRT sites. These FRT sites will permit in vivo deletion of the neo cassette if required (Dymecki, 1996) . The Pitx3 flox-neo allele was generated through homologous recombination in isogenic 129 mouse embryonic stem (ES) cells. Southern blotting using a 3′ probe located outside of the targeted sequences (Fig. 5A ) identified 7 correctly targeted clones among ≈ 600 tested (Fig. 5B) . Of three ES clones that were selected and used for blastocyst injection, two transmitted the floxed allele to the germline and were interbred with C57BL6 and 129SV females. Pitx3 +/flox mice obtained in both genetic backgrounds were mated with mice expressing Cre recombinase under the control of the CMV promoter. Deletion of the third exon of the Pitx3 gene was confirmed by PCR analysis (Fig. 5B) . Pitx3 +/− mice are viable, fertile and did not present any obvious phenotype. To analyze the effect of Pitx3 loss-of-function, Pitx3 +/− mice were intercrossed. Pitx3 −/− mice in both genetic backgrounds are viable, fertile, and have a life expectancy similar to wild-type siblings despite the absence of muscle Pitx3 protein (Figs. 7I-L) . Further investigation of Pitx3 −/− animals showed eye dysmorphogenesis (Fig. 5C) and selective loss of midbrain dopaminergic neurons, similar and not worse than aphakia mice (data not shown), but did not reveal any gross defect in musculature. Despite the absence of an apparent muscle phenotype, we investigated Pitx3 −/− embryos for expression of muscle markers that may reveal partial defects in myogenesis. No defects could be observed in e11.5 myotome (Figs. 6A-H) , in developing e11.5 intercostal muscles (Figs. 6I-N) , or in e13.5 FL muscle masses (Figs. 6O-R) or in e17.5 HL muscles (Figs. 6S-V) . Analysis of these different muscles at different times in their development indicated no differences in the patterns of expression for Pax3 (Fig. 6E) 
Compensation of Pitx3 deficiency by Pitx2
Since Pitx2 is expressed early during myogenic differentiation, we tested whether its expression might be altered in the absence of Pitx3. All muscles of Pitx3 −/− embryos examined showed no immunoreactivity for Pitx3 (Figs. 7I-L) whereas their wild-type counterparts showed expression in almost all nuclei (Figs. 7A-D) ; this included paravertebral (A, E, I, M), intercostal (B, F, J, N), lower back (C, G, K, O) as well as hip muscles (D, H, L, P) of e15.5 embryos. As shown previously (Fig. 4) , these muscles express very low levels of Pitx2 in wild-type embryos (Figs. 7E-H) . In striking contrast, the same muscles of Pitx3 −/− embryos exhibit robust Pitx2 immunoreactivity (Figs. 7M-P), indicating that Pitx2 expression is compensating for the absence of Pitx3 in these mutant animals. These data suggest that a feedback mechanism exists to maintain a level of Pitx transcription factors in muscle cells and that this mechanism can feedback onto the Pitx2 gene in absence of Pitx3 resulting in complete compensation (Fig. 8C) .
Discussion
The present work identifies the Pitx transcription factors as markers of skeletal muscle development (Fig. 8) . All skeletal muscles of the body and of the limbs express Pitx3 and this expression correlates closely with the expression of muscle markers and with the onset of myogenic differentiation. Pitx3 expression is preceded by Pitx2 in myotome and in limb muscle progenitors (Fig. 8A) . The knockout of Pitx3 expression does not impair muscle development in any significant way and it appears that Pitx2 completely compensates through enhanced and prolonged expression for the loss of Pitx3 (Figs. 6, 7 ).
Pitx2 in muscle progenitor cells
The earliest expression of Pitx2 appears to be in undifferentiated muscle progenitors of the myotome and ventro-lateral lip of the dermomyotome: these cells co-express Pax3 (Figs. 3A-C) and Pax7 (Figs. 3J-L) but do not express MF20 (Fig. 2L) . Progenitors of developing limb muscle masses also co-express Pax3 and Pitx2 (Fig. 3D-F) 2G-L). The expression of Pitx2 is strongest in early muscle cells from about e10.5 to e12.5. Thereafter, Pitx2 expression decreases in all muscle masses to be apparently replaced by Pitx3 (Figs. 4 and 8A) . In all developed muscles at e17.5, expression of Pitx2 is very discrete with a few nuclei often observed in clusters or within the same fiber (Figs. 7E-H) . The nature of those cells/fibers remains undefined. The coexpression of Pitx2 with Pax3 in proliferating BrdU-positive cells may be suggestive of a role in proliferation of progenitors (Kioussi et al., 2002; Baek et al., 2003; MartinezFernandez et al., 2006) . If so, its replacement by Pitx3 in differentiated post-mitotic muscle cells may be a way to maintain a Pitx-dependent myogenic program of gene expression independently of a Pitx2 proliferative activity that may not be shared by Pitx3. Should Pitx2 have such role in muscle progenitor proliferation, it is clear that it is not the sole regulator of proliferation as its maintenance in Pitx3 −/− muscles did not lead to bigger or dysmorphic muscles (data not shown).
A recent study of lacZ expression from a Pitx2 gene insertion showed similar Pitx2 expression patterns as we report here (Shih et al., 2007) . However, there appears to be significant discrepancies: for example, Shih et al. report lacZ expression in migrating myoblast and in late stage and adult muscles. We did not find significant Pitx2 immunoreactivity in these tissues compared to e10.5-e12.5 embryos (Figs. 2-4 ). These differences may be due to the stability of the lacZ protein and/or to the greater sensitivity of lacZ relative to immunoreactive Pitx2 detection. The lacZ expression may be indicative of weak Pitx2 promoter activity but very low protein accumulation: a similar situation has been proposed for Myf5 (Smith et al., 1994; Cornelison and Wold, 1997; Cooper et al., 1999; Beauchamp et al., 2000) . Similarly, the adult Pitx3 −/− muscles did not show more Pitx2 expression than wild-type animals (data not shown).
Pitx3 is expressed at the onset of muscle cell differentiation and is maintained in all skeletal muscles
In contrast to Pitx2, Pitx3 is rarely associated with phospho-H3-positive cells (Figs. 3Y, Z) and is less present in BrdUpositive cells (Figs. 3V-Z) . In myotome, Pitx3 is detected in cells that have entered myogenic differentiation as they are, for the most part, already positive for myogenin (Figs. 2M-R, 3Z ), for MF20 (Figs. 2S-X) and for MyoD (Fig. 3Z) . In contrast, Pitx3 expression in limb bud muscle masses is more widespread than myogenin (Figs. 3S-U) or MyoD (Fig. 3Z and data not shown). This may suggest that Pitx3 expression may precede MRFs in limb muscle cells: the detection of BrdU-and Pitx3-positive cells (Fig. 3Z) is consistent with this interpretation and may indicate induction of Pitx3 immediately following precursor cell cycle exit.
Pitx3 expression is maintained widely in more mature muscles (Fig. 4) . This expression of Pitx3 in differentiated cells suggests that it may also function in the maintenance of the muscle phenotype. This idea is entirely consistent with the observation that Pitx transcription factors contribute to transcriptional activation of many muscle-specific genes such myogenin, slow and fast troponin. Indeed, we have shown that the action of Pitx factors on muscle-specific regulatory sequences is exerted in synergism with MRFs. Transcriptional synergism between MRF heterodimers and Pitx factors is readily accounted for by the previous demonstration that the bHLH domains of ubiquitous bHLH factors that are the dimerization partners of MRFs, can physically interact with the Pitx homeodomain for transcriptional synergism: this paradigm was demonstrated previously for interactions between Pitx1 and bHLH heterodimers containing the neurogenic bHLH, NeuroD1 (Poulin et al., 2000) . It also appears that MRFs exert a positive feedback effect on the Pitx3 gene promoter (Coulon et al., submitted for publication) and MyoD was shown to be present at the Pitx3 promoter in ChIP experiments (Blais et al., 2005) . This positive feedback interaction between MRFs and Pitx3 taken together with the synergistic activation of muscle-specific genes by Pitx factors and MRF heterodimers strongly suggest that Pitx factors constitute an essential component of the myogenic differentiation and gene expression program.
